197 related articles for article (PubMed ID: 19366874)
1. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
Richey JM; Woolcott OO; Stefanovski D; Harrison LN; Zheng D; Lottati M; Hsu IR; Kim SP; Kabir M; Catalano KJ; Chiu JD; Ionut V; Kolka C; Mooradian V; Bergman RN
Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1311-8. PubMed ID: 19366874
[TBL] [Abstract][Full Text] [Related]
2. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
3. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant.
Herling AW; Kilp S; Juretschke HP; Neumann-Haefelin C; Gerl M; Kramer W
Int J Obes (Lond); 2008 Sep; 32(9):1363-72. PubMed ID: 18626484
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
5. Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
Poussin C; Hall D; Minehira K; Galzin AM; Tarussio D; Thorens B
PLoS One; 2008; 3(10):e3385. PubMed ID: 19030233
[TBL] [Abstract][Full Text] [Related]
6. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.
Herling AW; Kilp S; Elvert R; Haschke G; Kramer W
Endocrinology; 2008 May; 149(5):2557-66. PubMed ID: 18276749
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
8. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
[TBL] [Abstract][Full Text] [Related]
9. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020
[TBL] [Abstract][Full Text] [Related]
12. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.
Koolman AH; Bloks VW; Oosterveer MH; Jonas I; Kuipers F; Sauer PJ; van Dijk G
Int J Obes (Lond); 2010 Feb; 34(2):374-84. PubMed ID: 19844210
[TBL] [Abstract][Full Text] [Related]
13. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
[TBL] [Abstract][Full Text] [Related]
14. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
15. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
Kunz I; Meier MK; Bourson A; Fisseha M; Schilling W
Int J Obes (Lond); 2008 May; 32(5):863-70. PubMed ID: 18253160
[TBL] [Abstract][Full Text] [Related]
16. Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters.
Ho JM; Smith NS; Adams SA; Bradshaw HB; Demas GE
J Neuroendocrinol; 2012 Jul; 24(7):1030-9. PubMed ID: 22420341
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.
Zhang LN; Gamo Y; Sinclair R; Mitchell SE; Morgan DG; Clapham JC; Speakman JR
Obesity (Silver Spring); 2012 May; 20(5):954-62. PubMed ID: 22173576
[TBL] [Abstract][Full Text] [Related]
18. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
20. Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.
Vaidyanathan V; Bastarrachea RA; Higgins PB; Voruganti VS; Kamath S; DiPatrizio NV; Piomelli D; Comuzzie AG; Parks EJ
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E624-34. PubMed ID: 22761159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
